The most powerful
biomarker discovery platform

GEMMAai™

GEnoMic Marker Analyzer

AI-Powered platform for matching patients with right treatment

Most clinical trials fail
Most cancer treatmens have low efficacy

GEMMAai™ PLATFORM

utilises the most advanced technology (WGS), professional expertise in big data analysis, and an AI approach combined with clinical information to dramatically improve patient stratification for a variety of molecular therapies.

How do we do it?

Our platform was created to base medical decisions on individual patient characteristics, rather than on standard treatment guidelines. Its key strengths lie in whole-genome sequencing,clinical data implementation, the AI , and the expertise. GEMMAai is continuously developed by leading experts in the field, from specialists in AI to experienced genomic scientists, who supervise the feature extraction process to ensure the most relevant biological context.

Learn how we do it.

Our proprietary software
for data mining

5410
whole-genome sequence data
153
genomic paterns (features)
9
AI-powered assays

Our pipeline

Our AI-powered methodology can be used to build a model for any drug-response diagnostic tool, including PARP, CDK4/6 and mTOR inhibitors. Since AI can continuously learn from real-world genomic data, using our engine on larger patient cohorts will help us to identify new genomic patterns to build more accurate prediction models for any targeted therapy.

TUMOR
TYPE

WGS DATA

TARGETED THERAPY

DISCOVERY

PROTOTYPE ASSAY

ANALITYCAL VALIDATION

CLINICAL VALIDATION

REGULATORY APPROVAL

UPCOMING
MILESTONES

OVARIAN

512

Carboplatin / PARPi

Title

65%

FDA breakthrough device in Q3 2021

BREAST

2152

PARPi
CDK4/6i
Ant-HER2
mTORi
PIK3i

Title

40%

Title

20%

Title

40%

Title

15%

Title

15%

2 analytically validated diagnostic tools in Q1 2021

LUNG

1852

PARPi
immunotherapy

Title

10%

Title

10%

2 prototype assays in Q3 2021

FASETM

GENOMIC FEATURE DATABASE

YOUR inhibitor

Discovery and validation

AI-POWERED
STRATIFICATION DIAGNOSTIC TOOL

TUMOR TYPE: OVARIAN

WGS DATA

512

TARGETTED THERAPY

Carboplatin / PARPi

65%

UPCOMING MILESTONES

FDA breakthrough device in Q3 2021

TUMOR TYPE: BREAST

WGS DATA

2152

TARGETTED THERAPY

PARPi

40%

CDK4/6i

20%

Ant-HER2

40%

mTORi

15%

PIK3i

15%

UPCOMING MILESTONES

2 analytically validated diagnostic tools in Q1 2021

TUMOR TYPE: LUNG

WGS DATA

1852

TARGETTED THERAPY

PARPi

10%

immunotherapy

10%

UPCOMING MILESTONES

2 prototype assays in Q3 2021

FUSETM

WGS DATA

GENOMIC FEATURE DATABASE

TARGETTED THERAPY

YOUR inhibitor

DISCOVERY AND VALIDATION

AI-POWERED STRATIFICATION DIAGNOSTIC TOOL

Individual "Decision Tree" Construction

Random Forest Artificial Intelligence methodology based on Training Dataset

INSTEAD OF >1 000 SAMPLES, GEMMAaiTM

requires only 100 training data for a reliable output and achieves the optimal balance of sensitivity (recall) and precision.

Discrimination threshold

Learning curves

CARBOPLATIN/PARPi CLASSIFIER

_ALICE

ArtificiaL Intelligence ClassifiEr

NEW GLOBAL STANDARD IN OVARIAN ONCOLOGY THROUGH CONNECTING AI TECHNOLOGY TO WHOLE-GENOME DATA

Our proprietary software
for data mining

_ALICE is a Random Forest model, consisting of 100 decision trees. It analyses 44 genomic features associated with ovarian cancer treatment response. Apart from ‘gold standard’ biomarkers for HRD like BRCA1/2 mutations, deletions with microhomologies and tandem duplications, we have identified 3 novel biomarkers correlated with HRD and 22 important genomic biomarkers associated with PARPi clinical response.

Biomarker imporance

3
novel biomarkers correlated with HRD
22
novel important genomic biomarkers associated with PARPi clinical response
19
‘gold standard’ biomarkers

_ALICE tech note

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque non sodales massa, sit amet venenatis diam. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Etiam a imperdiet nulla.

Download Tech Note



    I'm a patientI'm a doctorI'm a student
    I have read and agree to privacy policy and terms of service
    privacy policy
    terms of service

    Any questions?

    Contact us

      I have read and agree to privacy policy and terms of service
      privacy policy | terms of service

      In a hurry?

      Download a leaflet



        I'm a patientI'm a doctorI'm a student
        I have read and agree to privacy policy and terms of service
        privacy policy
        terms of servic